Symbiotec Pharmalab Gets US FDA EIR for Pithampur Facility

Symbiotec Pharmalab Limited has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (U.S. FDA) for its manufacturing facility located in Pithampur, Madhya Pradesh, India. The facility was classified with a Voluntary Action Indicated (VAI) status following the inspection, which took place from August 10 to August 14, 2026. This VAI classification indicates that while some issues may have been noted, they do not currently warrant significant regulatory action, suggesting the facility meets acceptable standards for U.S. FDA compliance. This development is positive for the company's export capabilities and market access to the United States.